

## Wissenschaftliche Publikationen Sarkomforschung

Beldjord, K., Chevret, S., Asnafi, V., Huguet, F., Boulland, M. L., Leguay, T., Thomas, X., Cayuela, J. M., Grardel, N., Chalandon, Y., *et al.* (2014). Oncogenetics and minimal residual disease are independent outcome predictors in adult patients with acute lymphoblastic leukemia. *Blood* *123*, 3739-3749.

Satheesha, S. and **Schäfer, B.W.** (2014) Cancer stem cells in pediatric sarcomas. In: *Stem Cells and Cancer stem cells* (Springer), Volume 11, 111-126.

Wachtel, M., Rakic, J., Okoniewski, M., Bode, P., Niggli, F., and Schäfer, B. W. (2014). FGFR4 signaling couples to Bim and not Bmf to discriminate subsets of alveolar rhabdomyosarcoma cells. *International journal of cancer Journal international du cancer* *135*, 1543-1552.

Herrero Martin, D., Boro, A., and Schäfer, B. W. (2013). Cell-based small-molecule compound screen identifies fenretinide as potential therapeutic for translocation-positive rhabdomyosarcoma. *PloS one* *8*, e55072.

Meyer, C., Hofmann, J., Burmeister, T., Groger, D., Park, T. S., Emerenciano, M., Pombo de Oliveira, M., Renneville, A., Villarese, P., Macintyre, E., *et al.* (2013). The MLL recombinome of acute leukemias in 2013. *Leukemia* *27*, 2165-2176.

Schäfer, B. W., Koscielniak, E., Kovar, H., and Fulda, S. (2013). ESF-EMBO Symposium "Molecular Biology and Innovative Therapies in Sarcomas of Childhood and Adolescence" Sept 29-Oct 4, Polonia Castle Pultusk, Poland. *Frontiers in oncology* *3*, 142.

Boro, A., Pretre, K., Rechfeld, F., Thalhammer, V., Oesch, S., Wachtel, M., Schäfer, B. W., and Niggli, F. K. (2012). Small-molecule screen identifies modulators of EWS/FLI1 target gene expression and cell survival in Ewing's sarcoma. *International journal of cancer Journal international du cancer* *131*, 2153-2164.

Kovar, H., Alonso, J., Aman, P., Aryee, D. N., Ban, J., Burchill, S. A., Burdach, S., De Alava, E., Delattre, O., Dirksen, U., *et al.* (2012). The first European interdisciplinary ewing sarcoma research summit. *Frontiers in oncology* *2*, 54.

Okoniewski, M. J., Lesniewska, A., Szabelska, A., Zyprych-Walczyk, J., Ryan, M., Wachtel, M., Morzy, T., Schäfer, B., and Schlapbach, R. (2012). Preferred analysis methods for single genomic regions in RNA sequencing revealed by processing the shape of coverage. *Nucleic acids research* *40*, e63.

Burger, A., Koesters, R., Schäfer, B. W., and Niggli, F. K. (2011). Generation of a novel rtTA transgenic mouse to induce time-controlled, tissue-specific alterations in Pax2-expressing cells. *Genesis* *49*, 797-802.

Schrappe, M., Valsecchi, M. G., Bartram, C. R., Schrauder, A., Panzer-Grumayer, R., Moricke, A., Parasole, R., Zimmermann, M., Dworzak, M., Buldini, B., *et al.* (2011). Late MRD response determines relapse risk overall and in subsets of childhood T-cell ALL: results of the AIEOP-BFM-ALL 2000 study. *Blood* 118, 2077-2084.

Walter, D., Satheesha, S., Albrecht, P., Bornhauser, B. C., D'Alessandro, V., Oesch, S. M., Rehrauer, H., Leuschner, I., Koscielniak, E., Gengler, C., *et al.* (2011). CD133 positive embryonalrhabdomyosarcoma stem-like cell population is enriched in rhabdospheres. *PloSone* 6, e19506.

Bonapace, L., Bornhauser, B. C., Schmitz, M., Cario, G., Ziegler, U., Niggli, F. K., Schafer, B. W., Schrappe, M., Stanulla, M., and Bourquin, J. P. (2010). Induction of autophagy-dependent necroptosis is required for childhood acute lymphoblastic leukemia cells to overcome glucocorticoid resistance. *The Journal of clinical investigation* 120, 1310-1323.

Hajdin, K., D'Alessandro, V., Niggli, F. K., Schafer, B. W., and Bernasconi, M. (2010). Furin targeted drug delivery for treatment of rhabdomyosarcoma in a mouse model. *PloS one* 5, e10445.

Hecker, R. M., Amstutz, R. A., Wachtel, M., Walter, D., Niggli, F. K., and Schafer, B. W. (2010). p21Downregulation is an important component of PAX3/FKHR oncogenicity and its reactivation by HDAC inhibitors enhances combination treatment. *Oncogene* 29, 3942-3952.

Schafer, B. W., and Niggli, F. (2010). Multidisciplinary management of childhood sarcoma: time to expand. *Expert review of anticancer therapy* 10, 1163-1166.

Wachtel, M., and Schafer, B. W. (2010). Targets for cancer therapy in childhood sarcomas. *Cancer treatment reviews* 36, 318-327.

Zauner, L., Melroe, G. T., Sigrist, J. A., Rechsteiner, M. P., Dorner, M., Arnold, M., Berger, C., Bernasconi, M., Schaefer, B. W., Speck, R. F., and Nadal, D. (2010). TLR9 triggering in Burkitt's lymphoma cell lines suppresses the EBV BZLF1 transcription via histone modification. *Oncogene* 29, 4588-4598.

Almadori, G., Bussu, F., Galli, J., Rigante, M., Lauriola, L., Michetti, F., Maggiano, N., Schafer, B. W., Heizmann, C. W., Ranelletti, F. O., and Paludetti, G. (2009). Diminished expression of S100A2, a putative tumour suppressor, is an independent predictive factor of neck node relapse in laryngeal squamous cell carcinoma. *Journal of otolaryngology* 38, 16-22.

Grass, B., Wachtel, M., Behnke, S., Leuschner, I., Niggli, F. K., and Schafer, B. W. (2009). Immunohistochemical detection of EGFR, fibrillin-2, P-cadherin and AP2beta as biomarkers for rhabdomyosarcoma diagnostics. *Histopathology* 54, 873-879.

Meyer, C., Kowarz, E., Hofmann, J., Renneville, A., Zuna, J., Trka, J., Ben Abdelali, R., Macintyre, E., De Braekeleer, E., De Braekeleer, M., *et al.* (2009). New insights to the MLL recombinome of acute leukemias. *Leukemia* 23, 1490-1499.

Oesch, S., Walter, D., Wachtel, M., Pretre, K., Salazar, M., Guzman, M., Velasco, G., and Schafer, B. W. (2009). Cannabinoid receptor 1 is a potential drug target for treatment of translocation-positive rhabdomyosarcoma. *Molecular cancer therapeutics* 8, 1838-1845.

Witt, H., Hajdin, K., Iljin, K., Greiner, O., Niggli, F. K., Schafer, B. W., and Bernasconi, M. (2009). Identification of a rhabdomyosarcoma targeting peptide by phage display with sequence similarities to the tumour lymphatic-homing peptide LyP-1. *International journal of cancer Journal international du cancer* 124, 2026-2032.